Macular Degeneration Testimonials
Now I Can See
I am 75 years old and have been diagnosed with dry AMD. At the beginning, I could not see out of my right eye – my doctor told me it was 20/200, and told me about MaculaEye. I took it for 2 months, and now I can see. My vision went to 20/70, and I can see letters. Thank you TheraLife.
*Note: Results may vary.*
Improved Quality of My Life
I am 80 years old and diagnosed with wet macular degeneration in one eye – measured 20/800 with distortion. In one month of taking TheraLife, I improved to 20/200 and could see 3 lines, 15 letters. In 3 months, I was measured at 20/60, and now I can see 5 lines and 25 letters. Now I can drive and golf. MaculaEye has improved the quality of my life so much.
*Note: Results may vary.*
Could Not Live Without It
I have macular degeneration in both eyes. My doctor measured me 20/80 in one eye and 20/70 in the other. I could not see any lines or letters. In 3 months of taking TheraLife, my vision was improved to to 20/60 and 20/45. I can see 3 lines and 15 letters. Now I can drive. I could not live without it.
*Note: Results may vary.*
Vision is Almost Normal
I have had dry AMD for years. I see wavy lines on the Amsler Grid and fuzzy images that require the use of magnifying glass in order to read. After taking TheraLife MaculaEye for 1 month, I already noticed an improvement in my Amsler Grid readings. After 3 months, my vision is almost normal. I can drive and read without aids. I really notice the difference if I stop taking the TheraLife MaculaEye. I am now on 4 capsules of TheraLife MaculaEye per day, on maintenance, and am very happy. I will be happy to share my stories with you regarding TheraLife MaculaEye.
*Note: Results may vary.*
MaculaEye… Truly Remarkable
(Dr. Burton Worrell, Eye Doctor at advancevisioncenter.com:) We had a Dry AMD patient whose vision was at 20/1600. After taking MaculaEye, his vision improved to 20/800. A 50% improvement. Truly remarkable.
*Note: Results may vary.*
References
- 1.Wong WL, Su X, Li X, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health 2014;2:e106–16. 10.1016/S2214-109X(13)70145-1 [DOI] [PubMed] [Google Scholar]
- 2.Fleckenstein M, Keenan TDL, Guymer RH. Age-related macular degeneration. Nat Rev Dis Primers 2021;6. [DOI] [PubMed] [Google Scholar]
- 3.de Jong PTVM. Drusen, AMD, and history. Graefes Arch Clin Exp Ophthalmol 2015;253:2061–2. 10.1007/s00417-015-3180-2 [DOI] [PubMed] [Google Scholar]
- 4.de Jong PTVM. A historical analysis of the quest for the origins of aging macula disorder, the tissues involved, and its terminology. Ophthalmol Eye Dis 2016;8:5–14. 10.4137/OED.S40523 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.De Jong PTVM. Elusive drusen and changing terminology of AMD. Eye 2018;32:904–14. 10.1038/eye.2017.298 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Macular Photocoagulation Study Group . Subfoveal neovascular lesions in age-related macular degeneration. guidelines for evaluation and treatment in the macular photocoagulation study. macular photocoagulation Study Group. Arch Ophthalmol 1991;109:1242–57. [PubMed] [Google Scholar]
- 7.Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group . Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials – TAP report 1. Arch Ophthalmol 1999;117:1329–45. [PubMed] [Google Scholar]
- 8.Gragoudas ES, Adamis AP, Cunningham ET, et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004;351:2805–16. 10.1056/NEJMoa042760 [DOI] [PubMed] [Google Scholar]
- 9.Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 2005;36:331–5. 10.3928/1542-8877-20050701-14 [DOI] [PubMed] [Google Scholar]
- 10.Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419–31. 10.1056/NEJMoa054481 [DOI] [PubMed] [Google Scholar]
- 11.Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432–44. 10.1056/NEJMoa062655 [DOI] [PubMed] [Google Scholar]
- 12.Heier JS, Brown DM, Chong V, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 2012;119:2537–48. 10.1016/j.ophtha.2012.09.006 [DOI] [PubMed] [Google Scholar]
- 13.Age-Related Eye Disease Study Research Group . A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol 2001;119:1417–36. 10.1001/archopht.119.10.1417 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Klein RJ, Zeiss C, Chew EY, et al. Complement factor H polymorphism in age-related macular degeneration. Science 2005;308:385–9. 10.1126/science.1109557 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Edwards AO, Ritter R, Abel KJ, et al. Complement factor H polymorphism and age-related macular degeneration. Science 2005;308:421–4. 10.1126/science.1110189 [DOI] [PubMed] [Google Scholar]
- 16.Haines JL, Hauser MA, Schmidt S, et al. Complement factor H variant increases the risk of age-related macular degeneration. Science 2005;308:419–21. 10.1126/science.1110359 [DOI] [PubMed] [Google Scholar]
- 17.Hageman GS, Anderson DH, Johnson LV, et al. A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. Proc Natl Acad Sci U S A 2005;102:7227–32. 10.1073/pnas.0501536102 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Grzybowski A. Impact factor - benefits and limitations. Acta Ophthalmol 2015;93:201–2. 10.1111/aos.12579 [DOI] [PubMed] [Google Scholar]
- 19.Grzybowski A, Patryn R. Impact factor: universalism and reliability of assessment. Clin Dermatol 2017;35:331–4. 10.1016/j.clindermatol.2016.07.012 [DOI] [PubMed] [Google Scholar]
- 20.Krauthammer M, Moisseiev E. The 100 most cited articles on vitrectomy: a bibliographic perspective. Ophthalmol Retina 2020;4:361–8. 10.1016/j.oret.2019.10.016 [DOI] [PubMed] [Google Scholar]